News 2024-10-10
Connect with Porton J-STAR at AAPS PharmSci 360 2024 @ Booth 2431
The AAPS PharmSci 360, held from October 20-23, 2024, is an eminent event in the pharmaceutical industry, renowned for its convergence of key players, thought leaders, and innovative companies from across the globe. This year, Porton J-STAR invites you to connect with us at Booth 2431, where we will be exhibiting our end-to-end global CDMO service capabilities across both drug substance and drug product development and manufacturing, and the differentiated advantages these services offer to customers.
We employ advanced technologies and methodologies in our CDMO services. Our participation at AAPS PharmSci 360 reflects our dedication to innovation and excellence. With over 10,000 professionals and numerous exhibitors from various segments of the pharmaceutical industry, this conference is a premier platform for networking, collaboration, and showcasing cutting-edge advancements. It provides an unparalleled opportunity for us to engage with industry peers, explore potential partnerships, and drive forward the growth and innovation of the pharmaceutical sector.
As one of the world's leading CDMO companies, Porton J-STAR will be attending the event. Our expert speakers will deliver advanced technical insights and industry perspectives, offering attendees a deep dive into the latest developments.
For onsite meeting appointments, please contact:business@portonpharma.com.
Others
More
News 2025-04-16
Porton Advanced's End-to-End CDMO Solutions Accelerates IND Approval of Tasly's Innovative Dual-Targeting CAR-T Therapy
April 12, 2025 - Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD’s Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030). This breakthrough CAR-T therapy is indicated for recurrent glioblastoma (GBM).

News 2025-04-11
Porton Newsletter - Q1 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities